Egaten (Triclobendazole) Treatment Tablets: An effective treatment option for fascioliasis

Product name: Egaten (Triclobendazole)

Indications: Treatment of fascioliasis

Manufacturer: Novartis (Novartis)

Specifications: 250mg × 4Tablets

Main ingredients: Triclobendazole (Triclabendazole)

Packaging form: Blister packaging

Egaten is currently the only drug approved by the US FDA for the treatment of fascioliasis, and is a treatment recommended by the World Health Organization (WHO). The drug was announced by Novartis in February 2019 and is suitable for patients with fascioliasis over the age of 6.

EgatenInstructions for use

Egaten is a tablet, light red in color, with spots, capsule-shaped, biconvex design, with the words "EG GE" engraved on one side. Each tablet contains 250mg of triclabendazole, which has a strong therapeutic effect and can effectively inhibit the progression of fascioliasis.

Indications

Egatenis suitable for patients 6 years old and above, and is specifically used to treat fascioliasis. This is a chronic parasitic disease caused by flukes that can cause severe damage to vital organs such as the liver and bile ducts.

Dosage and usage

For patients 6 years of age and older, the recommended dose of Egaten is 10 mg/kg given in two divided doses 12 hours apart. If the dose cannot be adjusted precisely, it can be adjusted upward. Each tablet of Egaten can be swallowed directly, split in half and swallowed, or the crushed tablets can be taken with applesauce. It should be noted that it is stable for 4 hours after mixing.

Contraindications

EgatenContraindicated in patients with known hypersensitivity to triclabendazole or other benzimidazole derivatives. Also, patients who are allergic to any of the excipients in Egaten should avoid use.

drug interactions

There are currently no specific clinical drug interaction studies, but in vitro data indicate that triclabendazole may increase the plasma concentration of CYP2C19 substrates, so special attention is required when coadministered with CYP2C19 substrate drugs. During use, if abnormal increases in drug concentrations are found, it is recommended to recheck plasma concentrations after discontinuing triclabendazole treatment.

Warnings and Precautions

When usingEgaten, you need to pay attention to the problem of QT interval prolongation. Egatenmay cause prolongation of the QTc interval, especially when used together with CYP1A2 inhibitors. Patients with hepatic impairment may be at greater risk. Therefore, for patients with a history of prolonged QTc interval, or patients with electrolyte imbalance or liver dysfunction, electrocardiograms should be monitored regularly.

For use during pregnancy and lactation

While there are currently no detailed data on the use of Egatenby pregnant women, animal studies have shown that pregnant rats and rabbits showed no obvious fetal malformations during organogenesis. However, because the drug may be passed through breast milk, the risks should be weighed against the benefits when used by nursing mothers.

Used by the elderly

Current clinical studies have limited data on elderly patients 65 years old and above, so the use of EgatenElderly patients should be particularly cautious and adjust the dose based on liver, kidney or heart function.

overdose

A common symptom of overdose is nausea. If an overdose occurs, the patient should be treated under the guidance of a medical professional. ECG monitoring is necessary.

Common adverse reactions

In clinical studies, patients using Egaten reported fewer adverse reactions, usually no more than 2%. Common adverse reactions include constipation, biliary colic, joint pain, etc. However, patients with heavier helminth burdens may experience more significant side effects, such as abdominal pain, biliary colic, jaundice, etc., which may be secondary to the infection.

Egaten( triclabendazole) is the only FDA approved drug for the treatment of fascioliasis and has clear efficacy. By reducing the Fasciolia parasite burden, it can effectively alleviate disease symptoms and reduce the risk of long-term complications. For patients with fascioliasis, especially children and adults aged 6 years and above, Egaten is undoubtedly the most effective treatment option at present. However, when using this drug, patients should strictly follow the doctor's instructions and pay attention to possible adverse reactions and interactions to ensure safety and efficacy.

Reference materials:https://www.rxlist.com/egaten-drug.htm